During a study, researchers recruited 33 patients with type 1 diabetes who received weekly injections of alefacept, a drug used to treat psoriasis, for a period of 12 weeks. After completing the first 12 weeks of the study, patients were put on a 12-week break, and then underwent another 12 weeks of injections. During the course of these weeks, another group of patients received placebo injections.
Researchers found that patients who were treated with alefacept, were better able to preserve their insulin levels, compared to the group of patients who received placebo injections. The study, which was published in the Lancet Diabetes and Endocrinology journal, showed that over their treatment period, the group that was treated with the skin drug had fewer episodes of hypoglycemia and low blood glucose levels. Researchers say that although the study doesn’t provide a cure for diabetes, it can be used as a new way to stabilize the condition.